Jul 31, 2024 | News
New cognition/function and extensive plasma biomarker results of T3D-959 treatment from the Phase 2 PIONEER trial, in a modified intent-to treat population of mild to moderate Alzheimer’s patients will be presented at the upcoming Alzheimer’s Association International...
Jul 31, 2024 | News
Research Triangle Park, NC July 24, 2024 — T3D Therapeutics, Inc., a clinical stage drug development company engaged in the development of a new orally administered treatment for Alzheimer’s disease (AD), today announced that Dr. Robert Alexander has joined the...
Oct 4, 2023 | News
RESEARCH TRIANGLE PARK, N.C., Oct. 3, 2023 /PRNewswire/ — T3D Therapeutics, Inc. (“T3D”) a clinical stage drug development company engaged in the development of T3D-959, a new orally administered drug intended for the treatment of mild-to-moderate...
Apr 20, 2021 | News
RESEARCH TRIANGLE PARK, N.C., April 20, 2021 / T3D Therapeutics, Inc. (“T3D”), a clinical stage drug development company engaged in the development of T3D-959, a new orally administered treatment for Alzheimer’s disease (AD), announced today the...
Aug 27, 2020 | News
RESEARCH TRIANGLE PARK, N.C., Aug. 27, 2020 /PRNewswire/ — T3D Therapeutics, a clinical stage drug development company engaged in the development of T3D-959, a new orally administered treatment for Alzheimer’s disease (AD), announced today that it has...
